Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical vancomycin for catheter exit-site infection prevention/treatment in children on peritoneal dialysis
IRCT20240106060632N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vancomycin, sponsored by Mashhad University of Medical Sciences. Primary endpoint: Recovery of infection based on clinical improvement. Started Aug 2024; status: completed.
02
Drugs
vancomycin
Beyond the preview
Go deeper on IRCT20240106060632N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240106060632N1.